Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Seres Therapeutics Inc (MCRB)

Seres Therapeutics Inc (MCRB)
8.1600 +7.7900 (+2105.41%) 16:00 ET [NASDAQ]
8.1600 x 53 8.5600 x 24
Realtime by (Cboe BZX)
8.1600 x 53 8.5600 x 24
Realtime - - (-) -
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
7.1800
Day High
8.6400
Open 7.6200
Previous Close 0.3700 0.3700
Volume 275,581 275,581
Avg Vol 80,611 80,611
Stochastic %K 8.75% 8.75%
Weighted Alpha -47.43 -47.43
5-Day Change -4.6260 (-34.87%) -4.6260 (-34.87%)
52-Week Range 7.1800 - 30.6000 7.1800 - 30.6000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,228
  • Shares Outstanding, K 174,359
  • Annual Sales, $ 0 K
  • Annual Income, $ 140 K
  • EBIT $ -121 M
  • EBITDA $ -114 M
  • 60-Month Beta 2.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.58

Options Overview Details

View History
  • Implied Volatility 0.00% ( -217.42%)
  • Historical Volatility 144.54%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 554.55% on 04/15/25
  • IV Low 0.00% on 04/22/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 132
  • Volume Avg (30-Day) 149
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 6,614
  • Open Int (30-Day) 11,403

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.03
  • Number of Estimates 3
  • High Estimate 0.14
  • Low Estimate -0.12
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +88.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.1800 +20.33%
on 04/22/25
Period Open: 14.2260
15.2000 -43.16%
on 03/27/25
-5.5860 (-39.27%)
since 03/21/25
3-Month
7.1800 +20.33%
on 04/22/25
Period Open: 18.2300
19.0480 -54.64%
on 01/23/25
-9.5900 (-52.61%)
since 01/22/25
52-Week
7.1800 +20.33%
on 04/22/25
Period Open: 12.4920
30.6000 -71.76%
on 07/18/24
-3.8520 (-30.84%)
since 04/22/24

Most Recent Stories

More News
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

MCRB : 8.1600 (+9.06%)
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

MCRB : 8.1600 (+9.06%)
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

MCRB : 8.1600 (+9.06%)
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

MCRB : 8.1600 (+9.06%)
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

MCRB : 8.1600 (+9.06%)
Seres Therapeutics to Present at J.P. Morgan Healthcare Conference, Highlighting SER-155 Breakthrough Therapy Designation

Seres Therapeutics will present at the J.P. Morgan Healthcare Conference, focusing on SER-155's potential to reduce bloodstream infections.Quiver AI SummarySeres Therapeutics, Inc. has announced that CEO...

MCRB : 8.1600 (+9.06%)
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

MCRB : 8.1600 (+9.06%)
Seres Therapeutics Announces FDA Breakthrough Therapy Designation for SER-155 Following Promising Phase 1b Clinical Results

The FDA granted SER-155 Breakthrough Therapy designation for reducing bloodstream infections in allo-HSCT patients, supported by promising Phase 1b clinical data.Quiver AI SummarySeres Therapeutics announced...

MCRB : 8.1600 (+9.06%)
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

MCRB : 8.1600 (+9.06%)
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

MCRB : 8.1600 (+9.06%)

Business Summary

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 8.9120
2nd Resistance Point 8.5940
1st Resistance Point 8.0380
Last Price 8.1600
1st Support Level 7.1640
2nd Support Level 6.8460
3rd Support Level 6.2900

See More

52-Week High 30.6000
Fibonacci 61.8% 21.6536
Fibonacci 50% 18.8900
Fibonacci 38.2% 16.1264
Last Price 8.1600
52-Week Low 7.1800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro